BTAI Investors Should Contact Robbins LLP About Participating in the Class Action Against BioXcel Therapeutics SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioXcel...

BioXcel Therapeutics, Inc. Investors: Contact Robbins LLP if You Incurred Significant Losses in BTAI NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioXcel...

BioXcel Therapeutics, Inc. (BTAI) Sued by Shareholders: BTAI Investors Should Contact Robbins LLP for Information About Their Rights SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioXcel...

BioXcel Therapeutics, Inc. (BTAI) Investor Alert: Robbins LLP Reminds Investors of Class Action Against BioXcel Therapeutics, Inc. SAN DIEGO, July 13, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioXcel...